E
Elisabeth Lange
Researcher at Hamm AG
Publications - 26
Citations - 1363
Elisabeth Lange is an academic researcher from Hamm AG. The author has contributed to research in topics: Rituximab & Bendamustine. The author has an hindex of 12, co-authored 26 publications receiving 1066 citations.
Papers
More filters
Journal ArticleDOI
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Barbara Eichhorst,Anna-Maria Fink,Jasmin Bahlo,Raymonde Busch,Gabor Kovacs,Christian Maurer,Elisabeth Lange,Hubert Köppler,Michael G. Kiehl,Martin Sökler,Rudolf Schlag,Ursula Vehling-Kaiser,Georg Köchling,Christoph Plöger,Michael Gregor,Torben Plesner,Marek Trneny,Kirsten Fischer,Harmut Döhner,Michael Kneba,Clemens-Martin Wendtner,Wolfram Klapper,Karl-Anton Kreuzer,Stephan Stilgenbauer,Sebastian Böttcher,Michael Hallek +25 more
TL;DR: The combination of fludarabine, cyclophosphamide, and rituximab remains the standard front-line therapy in fit patients with chronic lymphocytic leukaemia, but bendamustine and riteximab is associated with less toxic effects.
Journal ArticleDOI
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
Richard F. Schlenk,Richard F. Schlenk,Daniela Weber,Walter Fiedler,Helmut R. Salih,Gerald Wulf,Hans Salwender,Thomas Schroeder,Thomas Kindler,Michael Lübbert,Dominik Wolf,Jörg Westermann,Doris Kraemer,Katharina Götze,Heinz-August Horst,Jürgen Krauter,Michael Girschikofsky,Mark Ringhoffer,Thomas Südhoff,Gerhard Held,Hans-Günter Derigs,Roland Schroers,Richard Greil,Martin Grießhammer,Elisabeth Lange,Alexander Burchardt,Uwe M. Martens,Bernd Hertenstein,Lore Marretta,Michael Heuser,Felicitas Thol,Verena I. Gaidzik,Wolfgang Herr,Julia Krzykalla,Axel Benner,Konstanze Döhner,Arnold Ganser,Peter Paschka,Hartmut Döhner +38 more
TL;DR: A phase 2 hypothesis-generating trial to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls.
Journal ArticleDOI
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Karolin Behringer,Helen Goergen,Felicitas Hitz,Josée M. Zijlstra,Richard Greil,Jana Markova,Stephanie Sasse,Michael Fuchs,Max S. Topp,Martin Soekler,Stephan Mathas,Julia Meissner,Martin Wilhelm,Peter Koch,Hans-Walter Lindemann,Enrico Schalk,Robert Semrau,Jan Kriz,Tom Vieler,Martin Bentz,Elisabeth Lange,Rolf Mahlberg,Andre Hassler,Martin Vogelhuber,Dennis Hahn,Jörg Mezger,Stefan W. Krause,Nicole Skoetz,Boris Böll,Bastian von Tresckow,Volker Diehl,Michael Hallek,Peter Borchmann,Harald Stein,Hans Theodor Eich,Andreas Engert +35 more
TL;DR: Non-inferiority of the experimental variants compared with ABVD in terms of freedom from treatment failure (FFTF) is shown by excluding a difference of 6% after 5 years corresponding to a hazard ratio (HR) of 1.72, via a 95% CI.
Journal ArticleDOI
Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)
Barbara Eichhorst,Anna-Maria Fink,Raymonde Busch,Gabor G. Kovacs,Christian Maurer,Elisabeth Lange,Hubert Köppler,Michael G. Kiehl,Martin Soekler,Rudolf Schlag,Ursula Vehling-Kaiser,Georg Köchling,Christoph Plöger,Michael Gregor,Torben Plesner,Marek Trneny,Kirsten Fischer,Hartmut Döhner,Michael Kneba,Clemens-Martin Wendtner,Wolfram Klapper,Karl Anton Kreuzer,Stephan Stilgenbauer,Sebastian Böttcher,Michael Hallek +24 more
TL;DR: The CLL10 study as mentioned in this paper evaluated the efficacy and tolerance of BR in comparison to FCR in frontline therapy of fit CLL patients without del(17p) for advanced CLL.
Journal ArticleDOI
Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).
Mathias J. Rummel,Wolfgang Knauf,Martin Goerner,Ulrike Soeling,Elisabeth Lange,Bernd Hertenstein,Jochen Eggert,Georg Schliesser,Rudolf Weide,K. Blumenstengel,Ninia Detlefsen,Axel Hinke,Frank Kauff,Juergen Barth +13 more
TL;DR: Rituximab maintenance is part of a standard treatment approach for follicular lymphoma, however, it is not yet common practice in mantle cell lymphoma (MCL), and in this study it is Compounded with chemotherapy to extend survival in women with MCL.